Promising drug cocktail aims to shrink penile cancer before surgery
NCT ID NCT07518979
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This phase II trial tests a combination of two drugs—Becotatug vedotin (a targeted therapy that attacks cancer cells with a specific protein) and Pucotenlimab (an immunotherapy that boosts the immune system)—in men with advanced penile cancer that is hard to treat with surgery alone. About 60 participants will receive the drugs before surgery to see if it shrinks the tumor enough for complete removal. The goal is to improve outcomes and possibly reduce the extent of surgery needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Becotatug vedotin (targeted therapy) and Pucotenlimab (immunotherapy)
What this could lead to
If successful, this combination could shrink advanced penile cancer enough to allow complete surgical removal, potentially improving survival and reducing the need for more extensive surgery.
What could go wrong
This is an early phase II trial with only 60 participants, so results may not apply to everyone. Side effects like skin rash, immune reactions, and organ stress are possible, and the treatment may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PENILE SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••